Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer - Prager, Gerald W.; Taieb, Julien; Fakih, Marwan; Ciardiello, Fortunato; Van Cutsem, Eric; Elez, Elena; Cruz, Felipe M.; Wyrwicz, Lucjan; Stroyakovskiy, Daniil; Pápai, Zsuzsanna; Poureau, Pierre-Guillaume; Liposits, Gabor; et al. (The New England journal of medicine, 2023)
Keywords: Adult; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antiviral drugs; Bevacizumab; Bevacizumab - adverse effects; Bevacizumab - therapeutic use; Cancer; Cancer therapies; Chemotherapy; Clinical trials; Colonic Neoplasms - drug therapy; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Confidence intervals; Design; Disease control; Drug Combinations; Frontotemporal dementia; Gastroenterology; Gastrointestinal Tract Cancer; Hematology; Humans; Laboratories; Metastases; Metastasis; Monoclonal antibodies; Neutropenia; Oncology; Pyrrolidines - adverse effects; Pyrrolidines - therapeutic use; Questionnaires; Rectal Neoplasms - drug therapy; Survival; Targeted cancer therapy; Treatments in Oncology; Trifluridine - adverse effects; Trifluridine - therapeutic use; Tumors; Uracil; Vascular endothelial growth factor